Evidence map›Paper›PMID 36332058›Full record

ArticleBlood advances2023

Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrations.

Kylee H Maclachlan, Tina Bagratuni, Efstathios Kastritis, Bachisio Ziccheddu, Sydney Lu, Venkata Yellapantula, Chris Famulare, Kimon Argyropoulos, Andriy Derkach, Elli Papaemmanuil and 7 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 2 countries.

Kylee H MaclachlanMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-7873-4854
Tina BagratuniDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.ORCID 0000-0001-8695-0493
Efstathios KastritisDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.ORCID 0000-0001-8191-5832
Bachisio ZicchedduMyeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
Sydney LuDepartment of Medicine, Stanford University, Stanford, CA.
Venkata YellapantulaDepartment of Bioinformatics, Children's Hospital of Los Angeles, Los Angeles, CA.
Chris FamulareCenter for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.
Kimon ArgyropoulosLymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0003-1510-5887
Andriy DerkachDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0003-2178-8493
Elli PapaemmanuilDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Ahmet DoganHematopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-6576-5256
Alexander LesokhinMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-9321-702X
Saad Z UsmaniMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
C Ola LandgrenMyeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.ORCID 0000-0001-6485-4839
Lia M PalombaLymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Francesco MauraMyeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.ORCID 0000-0002-5017-1620
Meletios A DimopoulosDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
Memorial Sloan Kettering Cancer Center · USNational and Kapodistrian University of Athens · GRUniversity of Miami · USChildren's Hospital of Los Angeles · USStanford University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Tumor Biology Research ProgramP30CA240139 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI George S. Grills · 2019 to 2026
$24.1M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA240139
6 · The paper itself

Abstract

The genomic landscape of Waldenström macroglobulinemia (WM) is characterized by somatic mutations in MYD88, present from the precursor stages. Using the comprehensive resolution of whole genome sequencing (WGS) in 14 CD19-selected primary WM samples; comparing clonal and subclonal mutations revealed that germinal center (GC) mutational signatures SBS9 (poly-eta) and SBS84 (AID) have sustained activity, suggesting that the interaction between WM and the GC continues over time. Expanding our cohort size with 33 targeted sequencing samples, we interrogated the WM copy number aberration (CNA) landscape and chronology. Of interest, CNA prevalence progressively increased in symptomatic WM and relapsed disease when compared with stable precursor stages, with stable precursors lacking genomic complexity. Two MYD88 wild-type WGS contained a clonal gain affecting chromosome 12, which is typically an early event in chronic lymphocytic leukemia. Molecular time analysis demonstrated that both chromosomal 12 gain events occurred early in cancer development whereas other CNA changes tend to occur later in the disease course and are often subclonal. In summary, WGS analysis in WM allows the demonstration of sustained GC activity over time and allows the reconstruction of the temporal evolution of specific genomic features. In addition, our data suggest that, although MYD88-mutations are central to WM clone establishment and can be observed in precursor disease, CNA may contribute to later phases, and may be used as a biomarker for progression risk from precursor conditions to symptomatic disease.

Indexed as

Lymphoma, B-CellWaldenstrom MacroglobulinemiaDNA Copy Number VariationsGerminal CenterHumansMutationMyeloid Differentiation Factor 88Myeloid Differentiation Factor 88

Identifiers

PMID36332058
PMCPMC10027506
OpenAlexW4308256430

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.